According to AstraZeneca's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 64.8396. At the end of 2021 the company had a P/E ratio of 402.
Year | P/E ratio | Change |
---|---|---|
2021 | 402 | 880.4% |
2020 | 41.0 | -57.68% |
2019 | 96.8 | 116.68% |
2018 | 44.7 | 52.59% |
2017 | 29.3 | 48.32% |
2016 | 19.7 | -35.16% |
2015 | 30.4 | -57.6% |
2014 | 71.8 | 146.77% |
2013 | 29.1 | 207.22% |
2012 | 9.47 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
![]() Johnson & Johnson JNJ | 22.4 | -65.38% | ๐บ๐ธ USA |
![]() Novartis NVS | 28.3 | -56.35% | ๐จ๐ญ Switzerland |
![]() Pfizer PFE | 7.18 | -88.92% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | 22.9 | -64.64% | ๐บ๐ธ USA |
![]() Eli Lilly LLY | 49.9 | -23.11% | ๐บ๐ธ USA |
![]() Sanofi SNY | 18.7 | -71.15% | ๐ซ๐ท France |
![]() Biogen BIIB | 12.9 | -80.16% | ๐บ๐ธ USA |
![]() Merck MRK | 18.7 | -71.22% | ๐บ๐ธ USA |
![]() Bristol-Myers Squibb BMY | 25.0 | -61.40% | ๐บ๐ธ USA |
![]() GlaxoSmithKline GSK | 4.43 | -93.17% | ๐ฌ๐ง UK |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.